2017 Chemotherapy Vaccines 
Pharmacy Times
JUNE 27, 2025
Acalabrutinib had previously received approval in 2017 as a single agent for this same indication. Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. The recent application was granted both priority review and orphan drug designation.
Pharmacy Times
JUNE 27, 2025
In the 2017 book The Big Picture , author Sean Carroll seamlessly blends the scientific with the philosophical and comments that “life is not a substance, like water or rock; it’s a process, like fire or a wave crashing on the shore. Dutton; 2017. REFERENCES 1. The Big Picture: On the Origins of Life, Meaning, and the Universe Itself.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
AUGUST 7, 2025
Methods Patients aged 18 to 59 years with t-AML or AML-MRC treated with CPX-351 or 7+3 as induction chemotherapy between 2015 and 2022 at 3 National Cancer Institute–designated cancer centers were included. 4 These findings led to the 2017 FDA approval of CPX-351 for adult patients with t-AML or AML-MRC. Author Disclosures Brian A.
European Pharmaceutical Review
DECEMBER 12, 2023
IPH5201 is being investigated in a Phase II trial, MATISSE, in combination with durvalumab (anti-PD-L1) and chemotherapy, in patients with resectable early-stage NSCLC. In 2007, he became in charge for business development and in 2017, also became responsible of the portfolio strategy.
pharmaphorum
SEPTEMBER 8, 2020
In England for instance, the introduction of a biosimilar to prevent neutropenia in patients undergoing chemotherapy, resulted in a number of Strategic Health Authorities reassessing their guidance relating to this medicine. 2017;(13):47-64. Available at [link] [Last accessed: September 2020]. 10 Wait S, Han D, Muthu V, et al.
Hospital Pharmacy Europe
FEBRUARY 15, 2024
Bespoke, personalised blood cancer treatment was revolutionised by the approval of the first chimeric antigen receptor (CAR) T-cell therapy in 2017, and they continue to offer an improved quality of life for many patients. They are] administered by the same nurses who would normally give chemotherapy’, Dr Tucker says.
pharmaphorum
NOVEMBER 14, 2022
The narrower label for Zejula (niraparib) means it can only be used as second-line maintenance therapy after platinum-based chemotherapy in patients with these cancers whose tumours carry a germline BRCA mutation – around 15% of the population. The post GSK hits another oncology hurdle as Zejula use is limited again appeared first on.
Expert insights. Personalized for you.
Let's personalize your content